Stocks · News reference
DaVita, as an investor, reported successful clinical study results for the investigational X9 System, a device designed to assist with needle placement during hemodialysis.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
DaVita, an investor in medical technology company X9, Inc., acknowledged the FDA's Breakthrough Device Designation for X9's ultrasound system designed for hemodialysis vascular access.
Pomerantz LLP has announced an investigation into DaVita Inc. regarding potential securities fraud or unlawful business practices following a recent federal strategy announcement concerning the dialysis market.
DaVita issued a response to the U.S. Department of Health and Human Services (HHS) regarding the national kidney care plan, reaffirming its commitment to innovation, patient access, and choice.